Doxotero-50 Injection (Doxorubicin Hydrochloride Injection BP 50 mg)

Doxotero-50 Injection is a branded oncology injectable formulation containing doxorubicin hydrochloride, an anthracycline-class antineoplastic agent with established use in regulated cancer treatment settings. Presented as a lyophilized powder for injection, Doxotero-50 Injection is developed for professional handling within licensed pharmaceutical supply chains. AmeriDrugs supplies this product for export to authorized importers, distributors, hospitals, and pharmacies across regulated international markets.

Active Ingredient (API + Strength)

• Active Pharmaceutical Ingredient: Doxorubicin Hydrochloride BP

• Strength: 50 mg per vial

• Dosage Form: Lyophilized powder for injection

Therapeutic Use (Informational, Non-Advisory)
Doxorubicin hydrochloride belongs to the anthracycline group of anticancer medicines and is used within approved oncology treatment frameworks for a range of solid tumors and hematological malignancies. Doxotero-50 Injection is supplied for use in accordance with locally approved protocols and regulatory guidance. This information is provided strictly for product identification and regulatory transparency and does not constitute medical advice or treatment recommendations.

Dosage Form & Route of Administration

• Dosage Form: Lyophilized powder for injection

• Route of Administration: Intravenous use only

• Prescription Status: Prescription-only medicine

• Intended for professional preparation and administration within regulated healthcare environments

Quality & Manufacturing Standards
Doxotero-50 Injection is manufactured in compliance with current Good Manufacturing Practices (GMP) and applicable pharmacopeial standards. The lyophilization process supports product stability during storage and international transport. Each batch undergoes stringent quality control testing, including sterility, potency, and physicochemical evaluation, to meet global export and regulatory requirements.

Packaging Information (Export-Oriented)

• Primary Packaging: Glass vial containing lyophilized powder

• Secondary Packaging: Printed carton with regulatory-compliant labeling

• Packaging suitable for international oncology supply and distribution chains

• Export documentation and labeling support available based on destination market regulations

Target Buyers

• Licensed pharmaceutical importers and distributors

• Oncology hospitals and cancer treatment centers

• Retail and wholesale pharmacies operating under prescription regulations

• Government and private institutional procurement agencies

• International distributors specializing in oncology injectables

Regulatory & Compliance Note
Doxotero-50 Injection is a prescription-only oncology medicine intended for regulated pharmaceutical distribution. For intravenous use only. Not for direct consumer self-use. Product supply is subject to import authorization, local drug regulatory approvals, and institutional procurement policies in the destination country. AmeriDrugs adheres to international export compliance standards and supports required regulatory documentation.